Make it Newsworthy
When you reach that exciting stage in your startup journey and you’re ready to get the word out—STOP. It’s time to get your story straight. This session explores what’s newsworthy, what’s not and how the pandemic has changed media in the last 18-months. Learn how to communicate your science in a way that resonates with journalists and your audiences. Discover the best way to pitch a reporter, and what turn-off tactics to avoid. Let’s demystify the press release while we’re at it. Our panel of accomplished science reporters and PR experts will teach you what’s newsworthy and how to get your story out there.
Co-Hosted with LaunchBio
REGISTER FOR THIS EVENT HERE.
|Susan Stipa, President McDay, a CG Life agency|
Susan Stipa is EVP, Public Relations for CGLife. She has thirty years in the pharmaceutical, biotechnology, financial services and healthcare related businesses. Susan's chemical engineering background in pharma and biotech helps she and her team listen with a different ear, translating science for journalists and nimbly guiding strategic thought processes for clients, which help them claim unique corners of the market using earned media - that invaluable and (mostly) objective media viewpoint.
|Mandy Jackson, Managing Editor, US Commercial News at Scrip/Pink Sheet|
|Mandy Jackson is Managing Editor, US Commercial News, for Scrip and The Pink Sheet. Mandy reports on daily biopharma developments, writes feature stories and produces the Finance Watch column. She covers finance, dealmaking, clinical trial results, commercial competition and corporate strategy for companies ranging from start-ups to big pharma. Mandy also is interested in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, diversity in the biopharma industry and novel approaches to drug development. She has been a business reporter since 2000, covering biopharma, biotech law and commercial real estate.|
|Arthur Suckow, CEO DTx Pharma|
|Dr. Suckow received his BS from the University of Delaware and his PhD from University of California, San Diego. He has worked for Johnson & Johnson, AstraZeneca and Regulus Therapeutics. Dr. Suckow’s extensive experience in fatty acid pharmacology includes advancing small molecules targeting fatty acids and fatty-acid conjugated peptides into early clinical development. Dr. Suckow has received numerous awards including a Beckman Fellowship, NSF graduate research fellowship, a BIOCOM catalyst award and many others.|
|Kate Sheridan, General Assignment Reporter, STAT|
I cover biotech startups and the venture capital firms that back them for STAT, a dedicated biopharma publication owned by Boston Globe Media Partners. Billions of dollars flow each year through VCs to biopharma startups — especially to those in Boston. Where that money comes from and where it goes matters both to current investors and to future patients. I'm always looking for people who can help me better understand how biotech companies are built, how impactful science is done, and how tough decisions are made.